Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Researchers at Children's Hospital of Philadelphia have identified MAP2K4 gene variants as a cause of a previously unknown neurodevelopmental disorder. Studying 10 patients with these variants, they found symptoms including developmental delay, epilepsy, and congenital malformations. Using CRISPR-edited stem cell neurons, the team uncovered how disruptions to the JNK pathway drive the condition — opening the door to future targeted treatments.
Scientists at Children's Hospital of Philadelphia (CHOP) have identified a new genetic syndrome caused by variants in the MAP2K4 gene, with findings published in the American Journal of Human Genetics. MAP2K4 encodes an enzyme that activates the JNK pathway — a critical signaling route for healthy brain development. While MAP2K4 loss has previously been linked to cancer, its connection to neurodevelopmental disease had not been established until now.
The research team identified 10 patients with MAP2K4 variants — nine of which arose de novo (not inherited from either parent). These children presented with developmental delay, epilepsy, and congenital malformations. To understand the underlying biology, researchers used CRISPR-edited stem cell-derived neurons to model the disorder, revealing how MAP2K4 deficiency disrupts JNK signaling and impairs normal neurodevelopment.
Key Takeaways:
Why it matters: Only about half of children with suspected genetic syndromes receive a definitive diagnosis. Identifying MAP2K4 as a disease-causing gene gives families answers, expands research opportunities, and lays the groundwork for future treatments targeting this newly recognized patient population.
